Veru (VERU) Income from Discontinued Operations (2023 - 2024)
Veru (VERU) posted quarterly Income from Discontinued Operations of 78553.0 for Q4 2024, up 208.44% year-over-year from 25467.82 in Q1 2024, and down 82.66% quarter-over-quarter from 453116.0 in Q3 2024.
Veru (VERU) Income from Discontinued Operations (2023 - 2024) Analysis & Trends
Veru (VERU) has reported Income from Discontinued Operations for 2 consecutive years, with 78553.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Income from Discontinued Operations rose 208.44% year-over-year to 78553.0; the TTM figure through Sep 2025 stood at 78553.0 (down 89.17% YoY), while the FY2025 annual figure was 78553.0, down 89.17% from the prior year.
- Income from Discontinued Operations eased to 78553.0 in Q4 2024 per VERU's latest filing, from 453116.0 in the prior quarter.
- Across five years, Income from Discontinued Operations topped out at 453116.0 in Q3 2024 and bottomed at 72439.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 78,553.00 |
| Sep 30, 2024 | 453,116.00 |
| Jun 30, 2024 | 162,422.00 |
| Mar 31, 2024 | 182,002.00 |
| Dec 31, 2023 | -72,439.00 |